Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab Combined With VMAT in Elderly Nasopharyngeal Carcinoma
NCT03915132Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- May 2019
- Primary completion
- May 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab in nasopharyngeal carcinoma (NPC), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Complete Remission Rate at 4 months. Status: unknown.
02
Drugs
nimotuzumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03915132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03915132.